Additional Paid in Capital of CytoDyn Inc. from 31 May 2011 to 30 Nov 2025

Taxonomy & unit
us-gaap: USD
Description
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
Summary
CytoDyn Inc. quarterly Additional Paid in Capital in USD history and change rate from 31 May 2011 to 30 Nov 2025.
  • CytoDyn Inc. Additional Paid in Capital for the quarter ending 30 Nov 2025 was $794,919,000, a 1.1% increase year-over-year.
Source SEC data
View on sec.gov
Additional Paid in Capital, Quarterly (USD)
Additional Paid in Capital, YoY Quarterly Change (%)

CytoDyn Inc. Quarterly Additional Paid in Capital (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $794,919,000 +$8,461,000 +1.1% 30 Nov 2025 10-Q 09 Jan 2026 2026 Q2
Q3 2025 $792,564,000 +$6,690,000 +0.85% 31 Aug 2025 10-Q 10 Oct 2025 2026 Q1
Q2 2025 $790,495,000 +$16,781,000 +2.2% 31 May 2025 10-Q 09 Jan 2026 2026 Q2
Q1 2025 $787,618,000 +$33,246,000 +4.4% 28 Feb 2025 10-Q 14 Apr 2025 2025 Q3
Q4 2024 $786,458,000 +$38,986,000 +5.2% 30 Nov 2024 10-Q 14 Jan 2025 2025 Q2
Q3 2024 $785,874,000 +$50,433,000 +6.9% 31 Aug 2024 10-Q 15 Oct 2024 2025 Q1
Q2 2024 $773,714,000 +$42,444,000 +5.8% 31 May 2024 10-K 25 Jul 2025 2025 FY
Q1 2024 $754,372,000 +$39,165,000 +5.5% 29 Feb 2024 10-Q 15 Apr 2024 2024 Q3
Q4 2023 $747,472,000 +$54,914,000 +7.9% 30 Nov 2023 10-Q 16 Jan 2024 2024 Q2
Q3 2023 $735,441,000 +$47,709,000 +6.9% 31 Aug 2023 10-Q 23 Oct 2023 2024 Q1
Q2 2023 $731,270,000 +$60,257,000 +9% 31 May 2023 10-K 15 Aug 2024 2024 FY
Q1 2023 $715,207,000 +$56,758,000 +8.6% 28 Feb 2023 10-Q 10 Apr 2023 2023 Q3
Q4 2022 $692,558,000 +$66,000,000 +11% 30 Nov 2022 10-Q 09 Jan 2023 2023 Q2
Q3 2022 $687,732,000 +$114,137,000 +20% 31 Aug 2022 10-Q/A 13 Oct 2022 2023 Q1
Q2 2022 $671,013,000 +$138,982,000 +26% 31 May 2022 10-K 14 Sep 2023 2023 FY
Q1 2022 $658,449,000 +$191,670,000 +41% 28 Feb 2022 10-K 15 Aug 2022 2022 FY
Q4 2021 $626,558,000 +$188,491,000 +43% 30 Nov 2021 10-K 15 Aug 2022 2022 FY
Q3 2021 $573,595,000 +$185,191,000 +48% 31 Aug 2021 10-K 15 Aug 2022 2022 FY
Q2 2021 $532,031,000 +$159,730,000 +43% 31 May 2021 10-K 15 Aug 2022 2022 FY
Q1 2021 $466,779,000 +$174,949,994 +60% 28 Feb 2021 10-K 15 Aug 2022 2022 FY
Q4 2020 $438,067,000 +$191,448,970 +78% 30 Nov 2020 10-K 15 Aug 2022 2022 FY
Q3 2020 $388,404,000 +$149,943,887 +63% 31 Aug 2020 10-Q 09 Oct 2020 2020 Q1
Q2 2020 $372,301,000 +$147,124,000 +65% 31 May 2020 10-K 15 Aug 2022 2022 FY
Q1 2020 $291,829,006 +$83,950,502 +40% 29 Feb 2020 10-Q 09 Apr 2020 2020 Q3
Q4 2019 $246,618,030 +$53,114,352 +27% 30 Nov 2019 10-Q 09 Jan 2020 2020 Q2
Q3 2019 $238,460,113 +$70,938,266 +42% 31 Aug 2019 10-Q 08 Oct 2019 2020 Q1
Q2 2019 $225,177,000 +$65,412,389 +41% 31 May 2019 10-Q 10 Jan 2022 2021 Q2
Q1 2019 $207,878,504 +$52,164,403 +34% 28 Feb 2019 10-Q 09 Apr 2019 2019 Q3
Q4 2018 $193,503,678 +$60,893,742 +46% 30 Nov 2018 10-Q 09 Jan 2019 2019 Q2
Q3 2018 $167,521,847 +$41,414,506 +33% 31 Aug 2018 10-Q 09 Oct 2018 2019 Q1
Q2 2018 $159,764,611 +$38,027,690 +31% 31 May 2018 10-K 14 Aug 2019 2019 FY
Q1 2018 $155,714,101 +$34,286,636 +28% 28 Feb 2018 10-Q 09 Apr 2018 2018 Q3
Q4 2017 $132,609,936 +$19,324,006 +17% 30 Nov 2017 10-Q 08 Jan 2018 2018 Q2
Q3 2017 $126,107,341 +$17,398,670 +16% 31 Aug 2017 10-Q 10 Oct 2017 2018 Q1
Q2 2017 $121,736,921 +$14,428,988 +13% 31 May 2017 10-K 27 Jul 2018 2018 FY
Q1 2017 $121,427,465 +$19,610,752 +19% 28 Feb 2017 10-Q 13 Apr 2017 2017 Q3
Q4 2016 $113,285,930 +$30,404,030 +37% 30 Nov 2016 10-Q 13 Jan 2017 2017 Q2
Q3 2016 $108,708,671 +$35,085,496 +48% 31 Aug 2016 10-Q 12 Oct 2016 2017 Q1
Q2 2016 $107,307,933 +$46,541,886 +77% 31 May 2016 10-K 20 Jul 2017 2017 FY
Q1 2016 $101,816,713 +$80,494,141 +378% 29 Feb 2016 10-Q 13 Apr 2016 2016 Q3
Q4 2015 $82,881,900 +$61,981,941 +297% 30 Nov 2015 10-Q 11 Jan 2016 2016 Q2
Q3 2015 $73,623,175 +$53,385,283 +264% 31 Aug 2015 10-Q 09 Oct 2015 2016 Q1
Q2 2015 $60,766,047 +$40,665,613 +202% 31 May 2015 10-K 19 Jul 2016 2016 FY
Q1 2015 $21,322,572 +$1,621,277 +8.2% 28 Feb 2015 10-Q 10 Apr 2015 2015 Q3
Q4 2014 $20,899,959 +$1,496,482 +7.7% 30 Nov 2014 10-Q 12 Jan 2015 2015 Q2
Q3 2014 $20,237,892 +$1,288,185 +6.8% 31 Aug 2014 10-Q 10 Oct 2014 2014 Q1
Q2 2014 $20,100,434 +$2,321,573 +13% 31 May 2014 10-K 10 Jul 2015 2015 FY
Q1 2014 $19,701,295 +$2,947,223 +18% 28 Feb 2014 10-Q 11 Apr 2014 2014 Q3
Q4 2013 $19,403,477 +$3,381,727 +21% 30 Nov 2013 10-Q 13 Jan 2014 2014 Q2
Q3 2013 $18,949,707 +$9,318,535 +97% 31 Aug 2013 10-Q 15 Oct 2013 2014 Q1
Q2 2013 $17,778,861 +$9,758,328 +122% 31 May 2013 10-K 10 Jul 2014 2014 FY
Q1 2013 $16,754,072 +$9,786,059 +140% 28 Feb 2013 10-Q 12 Apr 2013 2013 Q3
Q4 2012 $16,021,750 +$9,353,451 +140% 30 Nov 2012 10-Q 14 Jan 2013 2013 Q2
Q3 2012 $9,631,172 +$3,512,514 +57% 31 Aug 2012 10-Q/A 08 Nov 2012 2013 Q1
Q2 2012 $8,020,533 +$2,143,392 +36% 31 May 2012 10-K 29 Aug 2013 2013 FY
Q1 2012 $6,968,013 29 Feb 2012 10-Q 16 Apr 2012 2012 Q3
Q4 2011 $6,668,299 30 Nov 2011 10-Q 17 Jan 2012 2012 Q2
Q3 2011 $6,118,658 31 Aug 2011 10-Q/A 30 Nov 2011 2012 Q1
Q2 2011 $5,877,141 31 May 2011 10-K 22 Aug 2012 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.